Skip to Content
Merck
  • Calycosin down-regulates c-Met to suppress development of glioblastomas.

Calycosin down-regulates c-Met to suppress development of glioblastomas.

Journal of biosciences (2019-09-11)
Xiaohu Nie, Yue Zhou, Xiaobing Li, Jie Xu, Xuyan Pan, Rui Yin, Bin Lu
ABSTRACT

The antitumor effect of calycosin has been widely studied, but the targets of calycosin against glioblastomas are still unclear. In this study we focused on revealing c-Met as a potential target of calycosin suppressing glioblastomas. In this study, suppressed-cell proliferation and cell invasion together with induced-cell apoptosis appeared in calycosin-treated U251 and U87 cells. Under treatment of calycosin, the mRNA expression levels of Dtk, c-Met, Lyn and PYK2 were observed in U87 cells. Meanwhile a western blot assay showed that c-Met together with matrix metalloproteinases-9 (MMP9) and phosphorylation of the serine/threonine kinase AKT (p-AKT) was significantly down-regulated by calycosin. Furthermore, overexpressed c-Met in U87 enhanced the expression level of MMP9 and p-AKT and also improved cell invasion. Additionally, the expression levels of c-Met, MMP9 and p-AKT were inhibited by calycosin in c-Met overexpressed cells. However, an AKT inhibitor (LY294002) only effected on MMP9 and p-AKT, not on c-Met. These data collectively indicated that calycosin possibility targeting on c-Met and exert an anti-tumor role via MMP9 and AKT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Calycosin, ≥98% (HPLC)